CN109069512B - 取代的氨基嘌呤化合物、其组合物以及相关治疗方法 - Google Patents

取代的氨基嘌呤化合物、其组合物以及相关治疗方法 Download PDF

Info

Publication number
CN109069512B
CN109069512B CN201780021651.0A CN201780021651A CN109069512B CN 109069512 B CN109069512 B CN 109069512B CN 201780021651 A CN201780021651 A CN 201780021651A CN 109069512 B CN109069512 B CN 109069512B
Authority
CN
China
Prior art keywords
cancer
purin
ylamino
pyran
cyclohexanecarboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780021651.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109069512A (zh
Inventor
约翰·F·博伊兰
戈登·L·布雷
埃伦·菲尔瓦罗夫
罗伯特·哈伯德
大卫·米科伦
希瑟·雷蒙
施弢
塔姆·M·特朗
辻俊哉
莉莉·L·王
徐水蟾
丹·朱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Publication of CN109069512A publication Critical patent/CN109069512A/zh
Application granted granted Critical
Publication of CN109069512B publication Critical patent/CN109069512B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780021651.0A 2016-04-01 2017-03-31 取代的氨基嘌呤化合物、其组合物以及相关治疗方法 Active CN109069512B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317412P 2016-04-01 2016-04-01
US62/317,412 2016-04-01
PCT/US2017/025252 WO2017173206A1 (en) 2016-04-01 2017-03-31 Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Publications (2)

Publication Number Publication Date
CN109069512A CN109069512A (zh) 2018-12-21
CN109069512B true CN109069512B (zh) 2022-06-14

Family

ID=59959573

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780021651.0A Active CN109069512B (zh) 2016-04-01 2017-03-31 取代的氨基嘌呤化合物、其组合物以及相关治疗方法

Country Status (15)

Country Link
US (1) US10576085B2 (enExample)
EP (1) EP3436018A4 (enExample)
JP (1) JP7014731B2 (enExample)
KR (1) KR102356433B1 (enExample)
CN (1) CN109069512B (enExample)
AU (1) AU2017241837B2 (enExample)
BR (1) BR112018070163A2 (enExample)
CA (1) CA3018986A1 (enExample)
CL (1) CL2018002787A1 (enExample)
EA (1) EA039392B1 (enExample)
IL (1) IL262007B2 (enExample)
MX (1) MX379513B (enExample)
NZ (1) NZ746554A (enExample)
SG (2) SG11201808388QA (enExample)
WO (1) WO2017173206A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
TWI757256B (zh) 2015-11-02 2022-03-11 美商纜圖藥品公司 轉染過程重排之抑制劑
KR102359735B1 (ko) 2016-03-31 2022-02-08 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
KR102359743B1 (ko) 2016-03-31 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌 유도체
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PT3436019T (pt) 2016-04-01 2021-11-04 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos
SG11201808237UA (en) 2016-04-01 2018-10-30 Janssen Pharmaceuticals Inc Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US11407715B2 (en) 2017-05-22 2022-08-09 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
BR112019024311A2 (pt) 2017-05-22 2020-07-28 Janssen Pharmaceuticals, Inc. derivados de indolina substituídos como inibidores da replicação viral do dengue
CN111432841A (zh) 2017-10-04 2020-07-17 细胞基因公司 顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的组合物和使用方法
JP7422084B2 (ja) 2018-04-03 2024-01-25 ブループリント メディシンズ コーポレイション Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤
EP3833372A4 (en) * 2018-08-10 2022-06-08 Blueprint Medicines Corporation TREATMENT OF EGFR MUTANT CANCER
AU2020257207A1 (en) * 2019-04-16 2021-11-25 Vivace Therapeutics, Inc. Bicyclic compounds
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
EP4061364A4 (en) * 2019-11-20 2023-09-13 Vivace Therapeutics, Inc. HETEROARYL COMPOUNDS
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
KR102664454B1 (ko) * 2021-08-03 2024-05-09 한국생명공학연구원 젬시타빈에 대한 민감성 향상을 위한 신규 표적 및 이의 활용
CN114681456A (zh) * 2022-02-23 2022-07-01 中山大学附属第六医院 Plx3397在结直肠癌的治疗中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
WO2012061057A1 (en) * 2010-10-25 2012-05-10 Signal Pharmaceuticals, Llc Methods of treatment and/or prevention of scleroderma, uv injury or sunburn, formation of scars or keloids by using haloaryl substituted aminopurines
CN103087066A (zh) * 2005-01-13 2013-05-08 西格诺药品有限公司 卤代芳基取代的氨基嘌呤、其组合物及其治疗方法
CN107001372A (zh) * 2014-10-06 2017-08-01 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物及其治疗方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
DE602004025504D1 (de) * 2003-12-23 2010-03-25 Novartis Ag Bicyclische heterocyclische p-38-kinase-inhibitoren
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
EP1951693A4 (en) 2005-11-18 2012-05-30 Astrazeneca Ab SOLID FORMULATIONS
CA2652263A1 (en) 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
NZ589053A (en) 2006-10-27 2012-03-30 Signal Pharm Llc Process of preparing 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
ES2400006T3 (es) 2008-04-23 2013-04-04 Farmasierra Manufacturing, S.L. Formulación farmacéutica mejorada a base de ibuprofeno y codeína
WO2011071491A1 (en) 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US9466042B2 (en) 2012-01-24 2016-10-11 International Business Machines Corporation Facilitating the design of information technology solutions
US20160082015A1 (en) 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
CN115131834A (zh) * 2015-08-13 2022-09-30 小米科技有限责任公司 移动设备及其屏幕模组、指纹采集方法、装置及电子设备
PT3436019T (pt) * 2016-04-01 2021-11-04 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103087066A (zh) * 2005-01-13 2013-05-08 西格诺药品有限公司 卤代芳基取代的氨基嘌呤、其组合物及其治疗方法
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
WO2012061057A1 (en) * 2010-10-25 2012-05-10 Signal Pharmaceuticals, Llc Methods of treatment and/or prevention of scleroderma, uv injury or sunburn, formation of scars or keloids by using haloaryl substituted aminopurines
CN107001372A (zh) * 2014-10-06 2017-08-01 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物及其治疗方法

Also Published As

Publication number Publication date
BR112018070163A2 (pt) 2019-01-29
JP2019510066A (ja) 2019-04-11
IL262007A (en) 2018-10-31
KR20180126497A (ko) 2018-11-27
IL262007B2 (en) 2023-04-01
EA201892229A1 (ru) 2019-03-29
CN109069512A (zh) 2018-12-21
US10576085B2 (en) 2020-03-03
MX379513B (es) 2025-03-11
KR102356433B1 (ko) 2022-01-27
WO2017173206A1 (en) 2017-10-05
CL2018002787A1 (es) 2019-01-18
EP3436018A1 (en) 2019-02-06
NZ746554A (en) 2023-03-31
MX2018011992A (es) 2019-01-24
SG11201808388QA (en) 2018-10-30
EA039392B1 (ru) 2022-01-21
US20170281633A1 (en) 2017-10-05
JP7014731B2 (ja) 2022-02-01
AU2017241837A1 (en) 2018-10-25
EP3436018A4 (en) 2019-11-13
CA3018986A1 (en) 2017-10-05
IL262007B (en) 2022-12-01
AU2017241837B2 (en) 2021-07-22
SG10202009589UA (en) 2020-10-29

Similar Documents

Publication Publication Date Title
CN109069512B (zh) 取代的氨基嘌呤化合物、其组合物以及相关治疗方法
AU2014254056B2 (en) Combination therapy comprising a TOR kinase inhibitor and an IMiD compound for treating cancer
AU2014253978B2 (en) Combination therapy comprising a TOR kinase inhibitor and a 5-Substituted Quinazolinone Compound for treating cancer
ES2823756T3 (es) Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
US9782427B2 (en) Methods for treating cancer using TOR kinase inhibitor combination therapy
CN109819649B (zh) 氨基嘌呤化合物的固体形式及其使用方法
CA2909579A1 (en) Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
ES2881863T3 (es) Métodos para tratar cáncer usando terapia de combinación de inhibidor de quinasa TOR con un inhibidor de histona desacetilasa
NZ629859B (en) Methods for treating cancer using tor kinase inhibitor combination therapy
HK1233943B (en) Methods for treating cancer using tor kinase inhibitor combination therapy
HK1233943A1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
NZ629860B (en) Methods for treating cancer using tor kinase inhibitor combination therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant